ATNM News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AT

Volume

172.58K

Next Earnings

November 13th

Loading chart

AT

ATNMActinium Pharmaceuticals, Inc

ATNM

Pay with—

Available Balance0.00

AT

Mkt Cap

$33.3M

Volume

172.58K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

Next Generation Antibody Therapeutics Market, 2nd Edition: Global Industry Trends and Forecast to 2035 | Immunocytokines and Combination Therapies Drive GrowthThe global next generation antibody therapeutics market is projected to grow from USD 5.45 billion to USD 5.76 billion by 2035, with a modest 1% CAGR. Growth is driven by advances in biotechnology, targeted treatments, and expanding clinical pipelines for cancer, rare diseases, and cardiovascular conditions. Immunocytokines and combination therapies are expected to demonstrate the strongest growth potential, while North America is projected to maintain approximately 64% market share.GlobeNewswire Inc. · Oct 9, 2026

Targeted Alpha Therapy Market Landscape Report 2026-2030: Clinical Trials Insights on 30 Drugs - Size, Regulatory Approvals, Proprietary Technologies, Therapeutic ApplicationsThe targeted alpha therapy market is experiencing rapid growth driven by advancements in alpha emitters like Actinium-225, Astatine-211, and Lead-212 across clinical stages. Over 30 drugs are in clinical trials, with promising results in treating metastatic and drug-resistant cancers including prostate cancer and hepatocellular carcinoma. Major pharmaceutical companies and emerging biotech firms are actively developing these therapies, with recent M&A activity including AstraZeneca's acquisition of Fusion Pharmaceuticals and Bristol Myers Squibb's acquisition of RayzeBio, positioning targeted alpha therapy as a future pillar of precision medicine.GlobeNewswire Inc. · Apr 21, 2026

Targeted Alpha Therapies Market to Grow at 44% CAGR Globally by 2030A new market research report reveals targeted alpha therapies (TAT) for cancer treatment are projected to grow from $199.6 million in 2024 to $1.1 billion by 2030, with a 44% CAGR, driven by precision medicine and unmet oncology treatment needs.GlobeNewswire Inc. · Oct 17, 2025

המועד האחרון לתביעה נגד ATNM: רוזן, משרד עורכי דין ידוע מאוד, מעודד את משקיעי Actinium Pharmaceuticals, Inc שצברו הפסדים של יותר מ- 100 אלף דולר, להבטיח ייעוץ לפני המועד האחרון החשוב של 27 במאי בתביעה ייצוגית בניירות ערך – ATNMRosen Law Firm is encouraging investors in Actinium Pharmaceuticals, Inc. (ATNM) who have lost more than $100,000 to seek legal counsel before the May 27 deadline for a securities class action lawsuit. The lawsuit alleges that the company made false and misleading statements about the likelihood of its Iomab-B drug candidate being approved by the FDA.GlobeNewswire Inc. · May 25, 2025

ATNM DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 27 Deadline in Securities Class Action – ATNMRosen Law Firm is encouraging investors of Actinium Pharmaceuticals, Inc. (ATNM) who have lost more than $100,000 to secure legal counsel before the May 27, 2025 deadline for a securities class action lawsuit.GlobeNewswire Inc. · May 25, 2025

ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitA class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (ATNM) for allegedly making materially false and misleading statements about the likelihood of FDA approval for its drug Iomab-B.GlobeNewswire Inc. · May 21, 2025

ATNM INVESTOR ALERT: Kirby McInerney LLP Reminds Actinium Pharmaceuticals, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action LawsuitActinium Pharmaceuticals, Inc. (ATNM) is facing a class action lawsuit due to alleged misleading statements about its lead product candidate, lomab-B, and its planned Biologics License Application (BLA) filing. The lawsuit alleges that the company misled investors about the likelihood of the BLA being accepted and approved by the FDA.GlobeNewswire Inc. · May 21, 2025

ROSEN, A TOP RANKED LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNMA class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (ATNM) for allegedly making false and/or misleading statements about its Iomab-B Biologics License Application, which the FDA is unlikely to accept or approve.GlobeNewswire Inc. · May 19, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNMPomerantz LLP announces a class action lawsuit against Actinium Pharmaceuticals, Inc. (ATNM) due to the FDA's determination that the company's Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B, causing a significant drop in the company's stock price.GlobeNewswire Inc. · May 18, 2025

ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLPActinium Pharmaceuticals, Inc. (ATNM) is facing a securities fraud lawsuit alleging the company made false and/or misleading statements about its Iomab-B BLA, which is unlikely to be approved by the FDA.GlobeNewswire Inc. · May 18, 2025

to start trading

AT

ATNMActinium Pharmaceuticals, Inc

ATNM

Pay with—

Available Balance0.00

Your PositionYou don't own any ATNM yet.

Related Tickers

Earnings